Breaking News

Celerion Expands Respiratory Capabilities

January 9, 2013

Adds on-site bronchoscopy suite

Celerion has expanded its respiratory therapeutic capabilities with the addition of a dedicated bronchoscopy suite at its Belfast, Northern Ireland facility. The Bronchoscopy Suite allows bronchoalveolar lavage (BAL) to be performed in the clinic using study participants from Celerion’s extensive database.
The Bronchoscopy Suite enhances the company’s ability to explore the expression and quantification of protein biomarkers within the fluid lining of the lower respiratory tract. BAL samples can be analyzed for a panel of customized biomarkers and helps to provide a more comprehensive picture of the performance of potential airway drug candidates.
“Celerion has successfully conducted a number of studies that include mild to moderate and severe asthmatics, COPD and cystic fibrosis patients. Due to an increasing demand from clients for analysis of BAL samples, the dedicated Bronchoscopy Suite offers on-site access to this procedure,” said Phil Bach, vice president of Clinical Research at Celerion. “This investment continues to demonstrate Celerion’s response to the market’s increasing demand for conducting Phase I studies in patients with access to more specialized techniques.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks